|
|
Article: Neurochem Slides 43 Percent On Alzhemed Phase III Failure.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
After six months of number crunching, Neurochem Inc. confirmed what most analysts already suspected: the North American Phase III trial of Alzhemed (tramiprosate) in Alzheimer's disease did not meet its primary endpoints.
Neurochem completed the trial in February, but results were repeatedly delayed as the Laval, Quebec-based company made adjustments to its statistical models. Last month, analysts Brian Lian of CIBC World Markets Corp. and Jonathan Aschoff of Brean Murray, Carret & Co. LLC both told BioWorld Today that the trial had likely failed.
Top-line data released on Sunday showed the 18-month trial did not meet its primary ...